Rapport Therapeutics, Inc.

Rapport Therapeutics 'Fully Prepared' to Launch Novel Epilepsy Drug RAP-219 Solo, CEO Says

- Rapport Therapeutics is advancing RAP-219, a first-in-class AMPA receptor modulator targeting TARPγ8, into Phase 3 trials for focal epilepsy. - Phase 2 results showed a 78% reduction from baseline in clinical seizure frequency, corroborated by objective electrographic biomarkers from implantable neurostimulation devices. - CEO Abraham Ceesay stated the company is "fully prepared" to commercialize RAP-219 independently, citing neuroscience as a field where emerging biotechs have successfully launched products. - The company is pursuing a strategic partnership to include China in its global Phase 3 development program while maintaining control over commercialization in other markets.